Daiichi Sankyo Scri Announce Phase 1/2 Trial Of Ds 7300 Continues To Show Promising Durable Response In Patients With Several Types Of Advanced Cancer

Daiichi Sankyo Scri Announce Phase 1/2 Trial Of Ds 7300 Continues To Show Promising Durable Response In Patients With Several Types Of Advanced Cancer

By, Admin 12 September 2022

Daiichi Sankyo And Sarah Cannon Research Institute (Scri) Announced That Extended Follow-Up Data From A Phase 1/2 Trial Of Ds-7300, A Specifically Designed Potential First-In-Class B7-H3 Directed Dxd Antibody Drug Conjugate (Adc), Continues To Show Promising Durable Tumour Response In Patients With Several Types Of Heavily Pretreated Cancers Including Lung, Prostate Or Esophageal Cancer. These Data Were Presented In A Proffered Paper Session (Abstract #453O) At The European Society Of Medical Oncology (#Esmo22) Congress.B7-H3 Is Overexpressed In A Wide Range Of Cancer Types, Including Lung, Prostate And Esophageal, And Its Overexpression Has Been Shown To Correlate With Poor Prognosis In Some Cancers, Making B7-H3 A Promising Therapeutic Target.A Response Rate Of 32% (95% Ci: 24-41) Was Observed With 38 Responses (33 Confirmed; 28%; 95% Ci: 20-37) In 118 Patients With Various Solid Tumours Including Small Cell Lung Cancer (Sclc), Squamous Non-Small Cell Lung Cancer (Nsclc), Metastatic Castration-Resistant Prostate Cancer (Crpc), Esophageal Squamous Cell Carcinoma (Escc), Head And Neck Squamous Cell Carcinoma (Hnscc) Or Endometrial Cancer Receiving Doses Of Ds-7300 Ranging From 4.8 Mg/Kg To 16.0 Mg/Kg.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!